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Abstract 
 
Chronic irreversible kidney disease requiring dialysis is uncommon in the neonate. Many 
such neonates are diagnosed following antenatal US with congenital abnormalities of the 
kidneys and urinary tract (CAKUT).  There is an increased incidence of prematurity and 
infants that are small for gestational age. Given the natural improvement in renal function 
that occurs in the neonatal period, some can, with careful management of fluid and 
electrolytes, be kept off dialysis until the creatinine reaches a nadir when a definitive plan 
can be made. There is a very high incidence of comorbidity and this affects survival, which 
overall is about 80% at 5 years. The multiple and complex ethical issues surrounding the 
management of these very young children are discussed. 
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Introduction 
 
The numbers of neonates requiring dialysis for chronic, irreversible kidney disease (CKD) are 
extremely low. Most registries present data for under 2 year olds rather than neonates, for 
which figures vary from 7 to 12 per million age related population. For example that would 
be 20 to 30 at anytime in the UK, with a population of 64 million, and 100-150 in the US, 
with a population of 325 million. The European Society for Pediatric Nephrology and 
European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA), 
the International Pediatric Peritoneal Dialysis Network (IPPN) and Australia and New 
Zealand (ANZDATA) registries have looked to specifically identify neonates within the infant 
group. 264 neonates started chronic dialysis in 32 countries between 2000 and 2011. They 
represented around 18% of under 2 year olds on dialysis in both eastern and western 
Europe but only 6.8% in Australia and New Zealand. In Japan, neonates were 8.6% of 
dialysed children less than 5 years of age1. These variations are likely to be related to local 
attitudes to termination of pregnancy following detection of a life threatening renal 
abnormality, attitudes to acceptance of such infants onto renal replacement therapy (RRT) 
programmes, and resources available.  When dialysis is started is also dependent on local 
experience and policies.  
 
The neonatal kidney 
 
Kidney development commences at five weeks gestation. By week nine the first glomeruli 
are formed and by week 34 nephrogenesis ceases, by which time there are the definitive 
numbers of around one million glomeruli in each kidney. Therefore the premature infant’s 
kidneys are particularly vulnerable to insult during the period of ongoing nephrogenesis. A 
bladder is detectable by week nine, and thereafter fetal urine contributes to over 90% of 
liquor volume. 
 
90% of infants pass urine within 24 hours. Plasma creatinine reflects maternal levels at birth, 
and may rise in the first 3 weeks of life in premature infants due to tubular reabsorption. 
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Plasma bicarbonate may be lower than expected as the renal threshold for bicarbonate is 
18-20mmol/l, rising to 24-26mmol/l by 1 year of age. 
 
The neonate is predisposed to acute kidney injury (AKI). Fluid homeostasis is compromised 
because the kidneys receive only 15-20% of the cardiac output (25% in adults). The 
glomerular filtration rate (GFR) in the premature infant is 10-15 and 15-20 (ml/min/1.73m2) 
in the term infant. These values double over the first 2 weeks after birth and then rise 
progressively to adult values of 80-120 by 1 to 2 years of age.  Maximum urine 
concentrating capacity is also low at birth (up to 600mOsm/kg) and increases over the first 2 
months of life and then progressively over the first year of life 
 
Factors predisposing the neonate with CKD to acute kidney injury (AKI) 
 
The proportion of babies requiring RRT that are premature or small for gestational age 
(SGA) is higher than that in babies of the equivalent gestation without CKD.  Up to one 
quarter is born prematurely and one fifth are SGA 2-4 compared to around 8% in otherwise 
normal pregnancies5. These infants are therefore subject to all the complications associated 
with low birth weight, including chronic lung disease and developmental abnormalities, as 
well as the potential for insult to the ongoing nephrogenesis that continues up to 34 weeks 
gestation.  
 
Premature and term neonates with CKD may have pulmonary hypoplasia, which occurs in 
association with oligohydramnios or grossly enlarged kidneys and are therefore more prone 
to birth asphyxia and chronic lung disease over and above the effects of prematurity. They 
are more likely to develop AKI due to exaggerated tubular electrolye and water losses and 
dehydration, accompanying comorbidities, surgery, sepsis and the use of nephrotoxic drugs, 
which are all factors that are more common in the neonate with CKD6. 
 
Common diagnoses in neonates requiring long term RRT 
 
The majority of children in whom a need for RRT presents in the neonatal period have 
congenital abnormalities of the kidneys and urinary tract (CAKUT).  Some children may have 
autosomal recessive polycystic kidney disease (ARPKD), with very large kidneys. Renal 
tubular dysgenesis is a rare cause. About 50% of these infants are diagnosed antenatally. 
This offers the benefits of antenatal counselling of families about the potential outcome of 
the pregnancy, and immediate optimization of medical intervention after birth. On the 
other hand we are not yet that good at predicting outcome on the basis of antenatal scans. 
Clearly the absence of kidneys is going to lead to a very bad prognosis, and often such 
foetuses do not survive or termination may be offered. However, foetal US and urinary  
investigations have not consistently been linked to outcome,  and even oligohydramnios, 
which is believed to be a hard sign of poor outcome, is not always predictive7. Therefore the 
family has to live with uncertainty throughout the pregnancy. 
 
When to start dialysis 
 
A clear-cut need to start dialysis is unusual, unless there is renal or tubular agenesis or 
anuria. Many infants, particularly those with CAKUT, have ongoing urine production and 
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with attention to fluid and electrolyte balance and nutrition, can be kept without dialysis 
until they have recovered from respiratory complications or show improvement in kidney 
function, which would be expected in all neonates over the first few weeks of life. Indeed 
some babies may show a surprising improvement in renal function, and 10% of neonates 
actually stop dialysis1. The extra time gained enables growth, postponing the technical 
difficulties associated with small size and allowing easier dialysis access. Indeed some babies 
may not need dialysis at all. It is a common concept that patients in renal failure need fluid 
restriction. However, for the child with CAKUT, this is rarely the case and is likely to worsen 
the situation. This is illustrated in case 1. 
 
Case 1 
A male foetus was diagnosed at 22 weeks with a left kidney with increased echogenicity, a 
right multicystic kidney and a thick walled bladder (Figure 1). There was oligohydramnios. 
He was born by spontaneous delivery at 33 weeks gestation, with a birth weight of 1.7kg. He 
did not require ventilation. He underwent urethral catheterisation, and was given IV fluids 
as 0.45% saline with dextrose, 80-100ml/kg/day. He was oliguric. His sodium and 
bicarbonate fell and his creatinine, potassium and urea rose progressively to reach 700 
mcmol/l, 7.0mmol/l and 40mmol/l respectively by 2 weeks of age. Dialysis was not thought 
to be a possibility by the referring centre. He was referred to another centre for a second 
opinion. He was found to be dehydrated. He was started on IV normal saline, feeds at full 
requirement, and sodium and bicarbonate supplements. He began to gain weight and his 
creatinine fell progressively to 200 mcmol/l, with accompanying improvement in his 
potassium and urea levels. Dialysis was not necessary. 
 
Prognostic indicators (Table 1) 
 
As well as birth weight, gestation and pulmonary hypoplasia, there are other factors that 
impact on outcome and therefore influence the decision of the physician whether or not to 
recommend dialysis. The most important of these is co morbidity. Estimates suggest that 
this is present in as much as 73% of neonates requiring RRT 1,8 and covers a complete 
spectrum of disabilities. Studies have linked comorbidity to poor outcome, with a five-fold 
higher mortality risk over 5 years in those with neurological disease1 and an increase in 
mortality over 20 years of over seven-fold8. Those with CAKUT do better than those with 
ARPKD, in whom pulmonary hypoplasia and liver disease can cause serious comorbidity. The 
presence of long-term oliguria is also an adverse factor for outcome as it is at all ages. 
Finally, management of infants on RRT is laborious and is not possible without the full 
commitment of the family and the medical team9. 
 
Resources (Table 2)10 
 
The costs of RRT are substantial, and are particularly high in the infant, both in the short 
term because of the need for frequent reviews of the dialysis regimen, feeds and 
medications; and in the long-term because of the requirement for a lifetime of therapy.  
Such costs inevitably affect a country’s ability to treat these infants, depending on available 
resources. Table 2 shows IPPN data on the number of children taken onto RRT programmes 
according to the gross national income per capita of the country. When this falls below 
$12,000, numbers of young children on RRT programmes drop significantly10. 
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Survival of neonates on RRT (figure 2). 
 
Survival of very young children on dialysis is good and similar to that in older children when 
the effects of comorbidity are removed8. Figure 2 shows the survival to age 5 years for the 
recent combined registries neonatal data between the years 2000 and 20111,  of US 
neonates and 1 month to 2 year olds in the era 1992 to 200511, and a further analysis over 3 
years in the US for the era 2000-201212. The first thing to notice is that the survival of the 
neonates is similar to that of the 1 month to 2 year olds. The second Is that the recent 
cohorts seems to have a better survival than the older ones, being 80% at 5 years in the 
combined registries and also 80% at 3 years in the US. This had been 60% at 5 years 
between 1992 and 2005, and this improvement is statistically significant12. However, the 
data has to be viewed in the context that, like all registries, we do not know its 
completeness. It is likely that not only have the sickest children been excluded, but also that 
others with equally poor renal function may not have been included because of purposeful 
delay in initiating dialysis. The importance of this is that the missing data will influence the 
survival and causes of death in the cohorts that have been treated.  Despite that, these data 
is very helpful when counseling families about the prognosis for their child.  
 
Heath related quality of life (HRQoL) 
 
The outcome for the future quality of life for the newborn is another important question 
that families want answered. In a follow up study of 41 young adults who had CKD stage 4/5 
from infancy, 13% were on dialysis and  87% had a transplant at the time of the analysis. 
54% had co-morbidities.  Lower HRQoL scores were associated with co-morbidities, being on 
dialysis, more than one treatment modality change and being of short stature. Compared to 
a healthy, age matched population, employment rates and educational were levels similar 
although HRQoL was lower in physical and social role limitation and general health 
perception. The scores were comparable to those needing RRT in later childhood13. Again,  
these data is very helpful when counseling families about the prognosis for their child. 
 
Ethical aspects of RRT in infants 
 
The decision as to whether to start RRT in the neonate can be fraught with complex ethical 
issues, particularly in the child with comorbidities that also affect their survival and quality 
of life, and in parts of the world with limited resources. The European Paediatric Dialysis 
Working Group Guidelines, drawn up in 2014, state that when deciding whether to start RRT 
in the infant, comorbidities, predicted quality of life for the child and family, availability of 
resources (both medical and those of the family support structure) and the prognosis and 
possibility for future transplantation should be taken into consideration. The guidelines also 
recommend that parents of the affected child should be actively involved in the decision-
making process14. Even with these guidelines it can be very difficult to decide whether RRT is 
the best and most appropriate next step and agreement between the parents and the 
medical team is not always the case.   
 
Views of paediatric nephrologists and the multidisciplinary team on starting RRT in 
neonates and infants 
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Even in well-resourced countries there is ambiguity amongst paediatric nephrologists as to 
whether RRT is justified in all newborn that require it, and particularly so in those with 
comorbidity15. In a survey of pediatric nephrology teams in Canada, Germany, Japan, the 
United Kingdom, and the United States in 2010, 30% of paediatric nephrologists said they 
would offer RRT to all neonates and 50% to all infants aged one to 12 months. 50% believed 
that parents can never refuse RRT for children aged 1 to 12 months, compared with 27% for 
younger infants. The most influential factor in rejecting RRT for infants was comorbidity. 
Interestingly, nurses were more likely to believe that parents have the right to refuse RRT 
for infants. Comorbidity was the commonest cause given for the reason not to treat. 73% 
believed that parents can refuse RRT in the neonate15. 
 
In a more recent survey of paediatric nephrologists undertaken at the ESPN annual meeting 
in 2012, 12% said they would recommend RRT to all neonates with ESKD and 5% said they 
would not offer it at all. However, for infants aged 1 to 12 months, opinions changed such 
that 31% would recommend RRT for all and no one stated that they would not offer it at all 
to any infant.  72% thought it was usually acceptable for parents to refuse treatment for 
their newborn, whereas only 50% thought this is acceptable for those ages 1 to 12 months. 
The reasons for this difference in attitude to neonates in comparison to infants are not 
clear, and are in contrast to a recent eloquent discussion of ethical issues in the neonate, 
which makes very forcefully the argument that a decision to treat a neonate differently from 
an older child is unjustified16. Factors affecting the decision making process  were ranked as 
follows: coexistent serious medical abnormalities the highest, followed by anticipated 
morbidity for a child, the family’s right to decide, the doctor’s/medical staff’s right to 
decide, the presence of oligoanuria, family socioeconomic status and finally 
hospital/government budget constraints (personal data, F Emma, L Rees).  
 
The role of ethics in decision making 
 
So, can ethics help us when faced with these circumstances? Ethics are a set of principles 
that distinguish between right and wrong. However, rarely is there one single ‘right’ way to 
do something. Ethics therefore provide a means of evaluating and choosing between 
different, often competing options and are about analysing values rather than facts. 
 
The UK Royal College of Paediatrics and Child Health have produced guidelines on 
withholding and withdrawing life-saving treatment. The guidelines state that treatments, 
now and in the future, must be ‘in the child’s best interests’. They also state that ‘It is 
ethically acceptable to limit treatment that is not in a child’s best interests’17. An action or 
intervention is defined as being in the child’s best interests if the benefits outweigh 
burdens, there is acceptable minimisation of harm, the child is treated fairly and justly and, 
in the case of older children, there is respect for as much autonomy (capacity for self-
directed, informed choice) as the individual is capable of exercising. However, sources of 
ethical conflict are rarely that simple to resolve. 
 
The French Neonatal Society states that assessment of the child’s future quality of life, 
rather than its chances of survival, is the determinant of whether lifesaving treatment is 
reasonable or unreasonable, i.e. in the child’s best interests18. The Nuffield Council on 
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Bioethics (UK) definitions of quality of life include survival without life support, life outside 
of hospital, ability to develop relationships and ability to gain pleasure from life19.  
 
Sources of ethical conflict 
As well as withholding or withdrawing life sustaining therapies, there are additional 
situations when ethical conflicts can arise. Amongst these are when application of clinical 
facts alone cannot determine what should be done, when there is disagreement about the 
right course of action; and when application of moral principles conflict. Below are some 
examples of such ethical conflicts. 
 
Case 2: Application of clinical facts alone cannot determine what should be done: 
 
Failure of PD access has made PD an impossibility for the future, and the only option is HD: 
 
A baby with an antenatal diagnosis of posterior urethral valves with severe oligohydramnios 
at 22 weeks was delivered following spontaneous onset of labour at 32 weeks. The birth 
weight was 2.4kg. A PD catheter was inserted on day 3 of life due to anuria. There was 
leakage around the catheter and it had to be changed on day 5 of life. The baby developed 
necrotizing enterocolitis with gangrenous gut and a severe peritonitis requiring catheter 
removal.  The only option was haemodialysis in this small infant whose peritoneum was 
unlikely to recover for use in the future. Should HD be recommended or should treatment 
be withdrawn at this stage? 
 
Case 3 There is disagreement about the right course of action 
 
Removal of kidneys in a child with Congenital Nephrotic Syndrome or ARPKD, considered to 
be lifesaving by the medical team, conflicts with parental views  
 
Termination was recommended following an antenatal diagnosis at 20 weeks gestation of 
bilateral large, bright kidneys with oligohydramnios.  The parents rejected termination. The 
infant was delivered at 36 weeks gestation with a birth weight of 2.8kg. He required 
resuscitation and high frequency oscillation. The kidneys filled the abdomen but the urine 
output was good (Figure 2). The baby could not be maintained without ventilation because 
of diaphragmatic compression by the kidneys. The parents refused the recommendation for 
nephrectomies. 
 
Case 3 Application of moral principles conflict 
 
Treatment of the child with severe co-morbidity 
 
An infant was born with multiple complex abnormalities including abnormal vision and 
hearing, cardiac abnormalities, microcephaly and bilateral renal abnormalities. The child 
needed dialysis but the medical staff believed that this would not be appropriate. The 
parents want all possible treatments to proceed. 
 
The law may be unhelpful in these situations. Although deliberate intention to cause or 
hasten a patient's death (euthanasia) is illegal, decisions about withholding or withdrawing 
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treatment are less black and white, and ethical conflicts require professionals to make value 
judgments to resolve them. Many hospitals have ‘ethical committees’ whose purpose is to 
lead and aid discussions about difficult cases, but they are for guidance rather than decision 
making.  
 
Is withholding or withdrawing life sustaining treatments ever acceptable? 
 
The French Neonatal Society Recommendations state that ‘Withholding or withdrawing life-
sustaining treatment may be acceptable, and unreasonable therapeutic obstinacy is 
condemned. To withhold or withdraw a life-sustaining treatment can be justified when the 
intention is to cease opposing, in an unreasonable manner, the natural course of a 
disease’18. A particularly difficult concept for affluent areas is the role of resources in the 
decision making process. Clearly there are countries who do not have the resources to 
support such expensive treatments. In 1995 UK neonatologists wrote that ‘It may well be 
ethical to withdraw [or withhold or limit] treatment on the grounds that greater benefit 
could be achieved by using the resources in other ways’20. Nearly twenty years later the 
debate continues, but there is not a country in the world that does not have to ration 
treatments in some ways.  
 
Conflicts in decision making responsibilities 
 
There is no international concordance about who should be responsible for decision making 
in ethical disputes, and opinions vary between countries. The US Presidential Commission 
for the Study of Bioethical Issues is an advisory panel of the nation’s leaders in medicine, 
science, ethics, religion, law, and engineering. The Bioethics Commission seeks to identify 
and promote policies and practices that ensure scientific research, health care delivery, and 
technological innovation are conducted in a socially and ethically responsible manner. The 
commission has divided ethical issues about treatment management into into 3 neat 
categories: those that are clearly beneficial, when treatment should be provided even if the 
parents do not consent; those that are clearly futile, when treatment should not be 
provided, even if parents want it; and those when outcomes are ambiguous or uncertain, 
when parents should be the final determiners of course of action21. However, although 
these guidelines are very neat they are over simplistic and it is rarely possible to make such 
distinctions. The French Neonatology Society recommends that although the parents must 
be involved in the decision process so that they form an alliance with the healthcare team, 
any crucial decision affecting the patient’s life calls for individual medical responsibility18. 
 
Are neonates treated differently to infants, older children and adults? 
 
In 1995 it was written that ‘Clinicians frequently give young patients more chances to revive 
from and survive their illnesses than they offer to older, particularly elderly, patients.  
Clinicians also seem more willing to impose greater burdens on children with fewer chances 
of success than adults.’ Conversely, a more review stated that ‘Dialysis is not a therapy that 
doctors feel to be morally obligatory in most cases. While many doctors recommend dialysis 
for most infants with ESKD, most are willing to provide only palliative care if that is what the 
parents want’16.  The conflicting nature of these statements reflect the individuality of each 
case such that generalisations are not possible or appropriate.  
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Conclusion 
The number of neonates requiring RRT is small. However, their outcome is good, and equal 
to that of infants, providing that they do not suffer from comorbidities. Ethical issues are 
complex and every chosen pathway must be in the child’s best interests. 
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Table 1 Factors affecting the prognosis of neonates needing RRT 
 
Birth weight and gestation 
Co-morbidity 
Aetiology of CKD 
Pulmonary hypoplasia 
Oliguria/residual renal function 
Family circumstances 
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Table 2  Effect of gross national income on numbers of young children taken onto RRT 
programmes10 
 
 
  
Age at start of 
dialysis 
Gross national income in $000s per capita 
 
>28 18-28 12-18 <12 
<1 year 19 18 16 2 
1–3 years  11 15 11 6 
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Figure 1 Antenatal US of a male foetus with a left kidney with increased echogenicity and a 
right multicystic kidney. 
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Figure 2. Survival of neonates and infants during 2 different eras in the US and ESPN/EDTA-
ERA, ANZDATA and Japanese registries. 
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Figure 3. Nephromegaly in a child with ARPKD, causing respiratory depression. 
 
 
